Handelsavisen
prelaunch
Companies Healthcare EPIT.TA
EP
EPIT.TA TASE (Tel Aviv) Medical Equipment, Supplies & Distribution

Epit.Ta

$689,90
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-4 475,1 %
ROE
-33,2 %
Net margin
-4 043,2 %
Debt / equity
0,21
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

EPIT.TA operates in the healthcare services and equipment industry, primarily engaged in the medical equipment, supplies, and distribution sector.

Business. EPIT.TA operates in the healthcare services and equipment industry, primarily engaged in the medical equipment, supplies, and distribution sector.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
ActivityHealthcare Services & Equipment
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-33,2 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning EPIT.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to EPIT.TA. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    EPIT.TA operates in the healthcare services and equipment industry, primarily engaged in the medical equipment, supplies, and distribution sector.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryMedical Equipment, Supplies & Distribution
    ActivityHealthcare Services & Equipment
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a low debt-to-equity ratio of 0.21, indicating a conservative leverage position. It maintains a strong liquidity position with a current ratio of 6.23, supported by $13.65 million in cash and equivalents. However, the company's operating cash flow is negative at -$7.66 million, and free cash flow is also negative at -$9.41 million, suggesting ongoing cash flow challenges.

    Profitability metrics are significantly negative, with a return on equity of -33.17% and a return on assets of -26.01%. These figures are well below the industry norms for medical equipment and supplies, indicating poor performance relative to its peers. The company reported a net loss of $8.61 million, with operating income also in the red at -$9.53 million.

    The company's revenue concentration is not explicitly detailed in the available data, but the absence of segment-specific revenue breakdowns suggests a lack of diversification. This could pose a risk if the company's primary revenue streams face disruption. The geographic exposure is also not specified, which limits the understanding of regional dependencies.

    The company's growth trajectory is uncertain, with no specific revenue growth projections provided. Historical revenue data shows a total of $213 million, but without prior period comparisons, it is difficult to assess growth trends. The negative operating and free cash flows indicate that the company is not generating sufficient internal funds to support expansion or debt servicing.

    Risk factors include a low liquidity score, which suggests potential challenges in meeting short-term obligations. The company has a low dilution risk, with no immediate filing-based liquidity or dilution flags detected. However, the negative cash flows and profitability metrics indicate operational risks that could affect long-term stability.

    Recent events and filings do not provide specific details on the company's operations or strategic initiatives. The absence of recent transcripts or significant filings suggests a lack of public disclosure on key business developments, which could affect investor confidence.

    Key takeaways
    • The company has a strong liquidity position with a current ratio of 6.23, supported by $13.65 million in cash and equivalents.
    • Profitability is significantly negative, with a return on equity of -33.17% and a return on assets of -26.01%.
    • The company's capital structure is conservative, with a low debt-to-equity ratio of 0.21.
    • There is no immediate filing-based liquidity or dilution risk, but the negative cash flows and profitability metrics indicate operational challenges.
    • The company's growth trajectory is uncertain, with no specific revenue growth projections provided.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $689,90
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $26.0M
    Net cash
    $8.1M
    Current ratio
    6.2
    Debt / equity
    0.2
    ROA
    -26.0%
    ROE
    -33.2%
    Cash conversion
    89.0%
    CapEx / revenue
    -8.6%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-4 475,1 %Bottom quartile
    Net Margin-4 043,2 %Bottom quartile
    ROE-33,2 %Bottom quartile
    Capex / Rev-859,6 %Bottom quartile
    D/E0,21Below median
    Cash Conv0,89Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • EPIT.TA Market data — financials · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    EPIT.TACanonical
    TASE (Tel Aviv) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage